Patent: 7,758,889
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 7,758,889
Title: | Fullerenes in targeted therapies |
Abstract: | Herein we disclose a composition, comprising a C.sub.n-Ab, wherein C.sub.n is a fullerene or nanotube comprising n carbon atoms, and Ab is a moiety comprising an antigen-binding site and is linked to the Cn. The composition can further comprise a therapeutic molecule associated with the C.sub.n-Ab. Also, we disclose a method of treating a disease in a mammal, comprising administering to the mammal an effective amount of the composition. |
Inventor(s): | Sagman; Uri (Toronto, CA), Rosenblum; Michael G. (Sugar Land, TX), Wilson; Lon J. (Houston, TX) |
Assignee: | Luna Innovations Incorporated (Roanoke, VA) |
Application Number: | 10/623,110 |
Patent Claims: | see list of patent claims |
Details for Patent 7,758,889
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2022-07-24 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2022-07-24 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |